NCT00603590View on ClinicalTrials.gov

Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions
Cardiovascular DiseaseHypertensionHyperlipidemiaHeart Disease
Interventions
DRUG

Polypill

Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily

DRUG

Placebo drug

Inactive tablet Once a day Identical in appearance to intervention drug

Trial Locations (1)

Unknown

Kalaleh Heart Study Center, Kalāleh

All Listed Sponsors
collaborator

University of Birmingham

OTHER

lead

Tehran University of Medical Sciences

OTHER

NCT00603590 - Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease | Biotech Hunter | Biotech Hunter